The August 2023 issue of the American Journal of Health Economics will feature a cluster of articles that examine the opioid crisis.
Novartis expands Scemblix label to first-line CML patients
Novartis’ chronic myeloid leukemia drug Scemblix will now be available to newly diagnosed patients, the FDA announced on Tuesday. Scemblix was first approved in 2021